WHAT WE DO
WORKING AT BENEVOLENT
FIND A JOB
NEWS & MEDIA
Benevolent News Hub
In the media
Will AI turbocharge the hunt for new drugs?
AstraZeneca doubles down on BenevolentAI drug hunting partnership, adding heart failure, lupus targets
AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio
How tech is changing healthcare
Please don’t use this sentence out of context
BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of context in information extraction.
Feb 3, 2022
BenevolentAI Appoints Daniel Neil as Chief Technology Officer
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Jan 21, 2022
Joanna Shields • J.P. Morgan Health Care Conference 2022
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, presented at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 19, 2022
World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19
The WHO has widened its COVID-19 treatment pool by adding baricitinib, the drug first identified as a COVID-19 treatment by BenevolentAI, to the top of its treatment guideline.
Jan 14, 2022
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
BenevolentAI and AstraZeneca add systemic lupus erythematosus and heart failure to their expanded AI drug discovery collaboration.
Jan 13, 2022
BenevolentAI to Present at the 40th Annual JP Morgan Healthcare Conference
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 6, 2022
It’s up to us: reflections on responsible innovation
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.
Dec 22, 2021
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca’s portfolio
Novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s AI-driven drug discovery platform, selected to enter AstraZeneca’s portfolio.
Dec 15, 2021
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Receive our latest news
events & Conferences
Putting the Tech in Biotech Conference w/ Joanna Shields
Goldman Sachs Annual Global Healthcare Conference w/ Nick Keher
World Economic Forum w/ Joanna Shields
LSX World Congress w/ Mark Davies
Contact us →
Company Registration: R.C.S. Luxembourg: B255412
Terms & Conditions
Privacy & Cookies Policy